Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

(2021) Johan A Maertens et al.   LANCET

Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor

(2021) Sabelle Jallow et al.   Journal of Fungi

Hope on the Horizon: Novel Fungal Treatments in Development

(2020) Adriana M Rauseo et al.   Open Forum Infectious Diseases

Acid suppression medications during hospitalization as a risk factor for recurrence of Clostridioides difficile infection: systematic review and meta-analysis

(2020) Palna Mehta et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics and Pharmacodynamics of Posaconazole

(2020) Lu Chen et al.   DRUGS

In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling

(2020) R. Díaz de León–Ortega et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

(2020) Mohd H. Abdul-Aziz et al.   INTENSIVE CARE MEDICINE

Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals

(2020) Katharina R. Beck et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)

(2020) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation

(2020) A. Gómez-López   CLINICAL MICROBIOLOGY AND INFECTION

Caspofungin: a review of its characteristics, activity, and use in intensive care units

(2020) Seyed MohammadReza Hashemian et al.   Expert Review of Anti-Infective Therapy

Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube

(2020) Erin K McCreary et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center

(2020) Andrew M Borman et al.   MEDICAL MYCOLOGY

Clinical and Microbiological Characterization of Invasive Pulmonary Aspergillosis Caused by Aspergillus lentulus in China

(2020) Shu-Ying Yu et al.   Frontiers in Microbiology

Review on Current Status of Echinocandins Use

(2020) Martyna Mroczyńska et al.   Antibiotics-Basel

Review of the Novel Investigational Antifungal Olorofim

(2020) Nathan P. Wiederhold   Journal of Fungi

Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist

(2020) Felix Bongomin et al.   Journal of Fungi

Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations

(2020) Christoph Zurl et al.   Journal of Fungi

Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis

(2020) Chris Kosmidis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective observational study

(2020) Dan Tang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain

(2020) Pilar Escribano et al.   CLINICAL MICROBIOLOGY AND INFECTION

Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling

(2020) Pablo Zubiaur et al.   CLINICAL PHARMACOKINETICS

Rare/cryptic Aspergillus species infections and importance of antifungal susceptibility testing

(2020) Chi‐Ching Tsang et al.   MYCOSES

Using Child‐Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model‐based Analysis

(2020) Taotao Wang et al.   PHARMACOTHERAPY

Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan

(2020) Takahiro Takazono et al.   Scientific Reports

The global impact of Aspergillus infection on COPD

(2020) Emily E. Hammond et al.   BMC Pulmonary Medicine

Attainment of therapeutic posaconazole serum levels during coadministration with rifampicin

(2020) Nicholas Power et al.   Journal of Global Antimicrobial Resistance

Sequestration of Voriconazole and Vancomycin Into Contemporary Extracorporeal Membrane Oxygenation Circuits: An in vitro Study

(2020) Genny Raffaeli et al.   Frontiers in Pediatrics

Remission of hepatotoxicity in chronic pulmonary aspergillosis patients after lowering trough concentration of voriconazole

(2020) Guo-Jie Teng et al.   World Journal of Clinical Cases

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections

(2020) Mahmoud Ghannoum et al.   Antibiotics-Basel

Novel Antifungal Agents and Their Activity against Aspergillus Species

(2020) Roya Vahedi-Shahandashti et al.   Journal of Fungi

In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species

(2020) Ashutosh Singh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

(2020) Philipp Koehler et al.   LANCET INFECTIOUS DISEASES

Treatment of Posaconazole-Induced Peripheral Neuropathy With Methylprednisolone and Magnesium Infusions: A Case Report

(2019) Sadia Hussain et al.   Open Forum Infectious Diseases

In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies

(2019) Olga Rivero-Menendez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

No Relevant Pharmacokinetic (PK) Interaction between Rezafungin and Nine Probe Drugs: Results from a Drug-Drug Interaction (DDI) Study

(2019) Voon Ong et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

(2019) Miao Zhao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease

(2019) S. Seyedmousavi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels

(2019) S. Kurland et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside

(2019) Marion Aruanno et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B

(2019) Jill Adler-Moore et al.   CLINICAL INFECTIOUS DISEASES

Ibrexafungerp: A novel oral glucan synthase inhibitor

(2019) M R Davis et al.   MEDICAL MYCOLOGY

When medicine transforms art

(2019) Sara Belga et al.   Transplant Infectious Disease

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

(2019) Roeland E Wasmann et al.   CLINICAL INFECTIOUS DISEASES

Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism

(2019) Minh-Vu H Nguyen et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients

(2019) Jamie John et al.   Expert Opinion on Drug Metabolism & Toxicology

An evaluation of nebulised amphotericin B deoxycholate (Fungizone ® ) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre

(2019) Akaninyene A. Otu et al.   MYCOSES

Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level

(2019) Jihyu Oh et al.   MYCOSES

Implications for IV posaconazole dosing in the era of obesity

(2019) Roeland E Wasmann et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation

(2019) Yanjun Zhao et al.   PHARMACOTHERAPY

The effect of the novel antifungal drug F901318 (Olorofim) on the growth and viability of Aspergillus fumigatus

(2018) Saskia du Pré et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of cumulative intravenous voriconazole dose on renal function in hematological patients

(2018) Takeo Yasu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

(2018) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

(2018) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacokinetics–pharmacodynamics of antifungal agents in the central nervous system

(2018) Katharine E Stott et al.   Expert Opinion on Drug Metabolism & Toxicology

A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminemia receiving continuous venovenous hemodiafiltration

(2018) Fekade B Sime et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Tolerability profile of the current antifungal armoury

(2018) Ahmad Mourad et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species

(2018) Nathan P Wiederhold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of nebulized liposomal amphotericin B in the treatment of ABPA in an HIV/HBV co-infected man: Case report and literature review

(2018) Magali Garcia et al.   JOURNAL OF ASTHMA

OUP accepted manuscript

(2018)   MEDICAL MYCOLOGY

Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives

(2018) Ana Alastruey-Izquierdo et al.   RESPIRATION

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy

(2018) Jeffrey D Jenks et al.   Drug Design Development and Therapy

Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis

(2018) Javier Martínez-Casanova et al.   Infection and Drug Resistance

Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects

(2018) Julian Lindsay et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study

(2018) Pieter P Lestrade et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis

(2018) Chris Kosmidis et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events

(2018) Felix Bongomin et al.   MYCOSES

Perfil farmacológico del isavuconazol

(2018) José Ramón Azanza Perea et al.   REVISTA IBEROAMERICANA DE MICOLOGIA

Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients

(2017) Romuald Bellmann et al.   INFECTION

In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates

(2017) J. B. Buil et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Echinocandins in antifungal pharmacotherapy

(2017) Akash Patil et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Graded isavuconazole introduction in a patient with voriconazole allergy

(2017) Megan K. Morales et al.   Transplant Infectious Disease

Desensitisation to liposomal amphotericin B

(2017) Bella Shadur et al.   Journal of Allergy and Clinical Immunology-In Practice

First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

(2017) Michael R Hodges et al.   Open Forum Infectious Diseases

Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin

(2016) Voon Ong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

(2016) Amit Desai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients

(2016) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Voriconazole Dosing in Obese Patients

(2016) Khalid Eljaaly et al.   CLINICAL INFECTIOUS DISEASES

Real-Life Use of Isavuconazole in Patients Intolerant to Other Azoles: Table 1.

(2016) Eloy E. Ordaya et al.   CLINICAL INFECTIOUS DISEASES

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions

(2016) Neil R. H. Stone et al.   DRUGS

Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis

(2016) Matt Shirley et al.   DRUGS

Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis

(2016) Haiying Jin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cross-reactivity between voriconazole, fluconazole and itraconazole

(2016) D. Benjamin Lash et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

Comparison between liposomal formulations of amphotericin B

(2016) Jill P Adler-Moore et al.   MEDICAL MYCOLOGY

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations

(2016) Suganthini Krishnan Natesan et al.   Infection and Drug Resistance

Echinocandins: The Expanding Antifungal Armamentarium

(2015) Daniel Aguilar-Zapata et al.   CLINICAL INFECTIOUS DISEASES

Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections

(2015) Kate McKeage   DRUGS

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

(2015) David W. Denning et al.   EUROPEAN RESPIRATORY JOURNAL

Dosing of antifungal agents in obese people

(2015) Kenna D. Payne et al.   Expert Review of Anti-Infective Therapy

Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients

(2014) Kim Vanstraelen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tissue Penetration of Antifungal Agents

(2014) T. Felton et al.   CLINICAL MICROBIOLOGY REVIEWS

Polypharmacy in patients hospitalised for acute exacerbation of COPD

(2014) J. Diez-Manglano et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA)

(2014) Livingstone Chishimba et al.   JOURNAL OF ASTHMA

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review

(2014) A. K. Polso et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Farmacología de los antifúngicos en el tratamiento de la aspergilosis

(2014) José Ramón Azanza et al.   REVISTA IBEROAMERICANA DE MICOLOGIA

The clinical spectrum of pulmonary aspergillosis

(2014) C. Kosmidis et al.   THORAX

Evaluation of intravenous voriconazole in patients with compromised renal function

(2013) Craig M Lilly et al.   BMC INFECTIOUS DISEASES

A Modern Series of Percutaneous Intracavitary Instillation of Amphotericin B for the Treatment of Severe Hemoptysis From Pulmonary Aspergilloma

(2013) Jared N. Kravitz et al.   CHEST

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

(2013) R. B. Moss   EUROPEAN RESPIRATORY JOURNAL

Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

(2013) Jodi Lestner et al.   Expert Opinion on Drug Metabolism & Toxicology

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

(2013) H. R. Ashbee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics of Posaconazole Within Epithelial Cells and Fungi: Insights Into Potential Mechanisms of Action During Treatment and Prophylaxis

(2013) Paolo Campoli et al.   JOURNAL OF INFECTIOUS DISEASES

Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature

(2013) Ritesh Agarwal et al.   MYCOSES

Administration of Voriconazole in Patients With Renal Dysfunction

(2012) D. Neofytos et al.   CLINICAL INFECTIOUS DISEASES

Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial

(2012) J. Cadranel et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Bronchial and alveolar components of exhaled nitric oxide and their relationship

(2012) Sylvia Verbanck et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy and safety of antifungal prophylaxis with oral itraconazole solution among patients receiving corticosteroids: who should be given prophylaxis?

(2011) Noriyoshi Iriyama et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Allergic Bronchopulmonary Aspergillosis and Related Allergic Syndromes

(2011) Celia Hogan et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Antifungal PK/PD Considerations in Fungal Pulmonary Infections

(2011) Alexander Lepak et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host

(2011) Dipen A. Patel et al.   JOURNAL OF MEDICAL ECONOMICS

Systematic Review and Meta-Analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal Infection

(2010) J. L. Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation

(2009) I. Spriet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Nebulized Liposomal Amphotericin B Prophylaxis for Aspergillus Infection in Lung Transplantation: Pharmacokinetics and Safety

(2009) Víctor Monforte et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Immediate cross-hypersensitivity between Micafungin and Caspofungin: A case report

(2009) Shruti Patel et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Amphotericin B lipid preparations: what are the differences?

(2008) J.P. Adler-Moore et al.   CLINICAL MICROBIOLOGY AND INFECTION

Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation

(2008) Stéphanie Ruiz et al.   INTENSIVE CARE MEDICINE